Internal Medicine, Infectious Disease · Longview, TX
NPI
1447505243
Since 2012
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
700 E Marshall Ave
Longview, TX, 75601
Phone (903) 315-1488
Groups this clinician bills Medicare through
Medicare paid, 2024
$213K
3,172 services
Medicare patients, 2024
453
Average age 74
Drug cost, 2024
$281K
922 prescriptions
Company payments, 2025
$23.34
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Celestine C Ishiekwene was code 99232 (hospital e&m - subsequent), 2,111 times for 374 patients. In total Celestine C Ishiekwene billed 3,172 services in 17 codes, and Medicare paid $213K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 2,111 | 374 | $58.99 | $125K |
| 99222 Hospital E&M - Initial | Facility | 344 | 291 | $98.41 | $34K |
| 99214 Office E&M - Established | Facility | 239 | 137 | $71.27 | $17K |
| 99215 Office E&M - Established | Facility | 162 | 80 | $102.51 | $17K |
| 99213 Office E&M - Established | Facility | 96 | 80 | $50.10 | $4,810 |
| 99231 Hospital E&M - Subsequent | Facility | 66 | 20 | $37.59 | $2,481 |
| 99223 Hospital E&M - Initial | Facility | 52 | 49 | $128.81 | $6,698 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 31 | 17 | $12.55 | $389 |
| 99205 Office E&M - New | Facility | 19 | 19 | $133.14 | $2,530 |
| 99204 Office E&M - New | Facility | 12 | 12 | $101.16 | $1,214 |
By year: 2022 $159K for 2,224 services; 2023 $205K for 2,964 services; 2024 $213K for 3,172 services.
Medicare prescription drug claims, 2024
In 2024, the drug Celestine C Ishiekwene prescribed most often to Medicare patients was Daptomycin, with 125 prescriptions and refills. In total Celestine C Ishiekwene wrote 922 Medicare prescriptions that cost $281K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Daptomycin Generic | 125 | 125 | 27 | $127K |
| Ertapenem Ertapenem Sodium | 105 | 105 | 44 | $42K |
| Ceftriaxone Ceftriaxone Sodium | 96 | 96 | 20 | $7,931 |
| Oxacillin Sodium Generic | 55 | 55 | 12 | $18K |
| Piperacillin-Tazobactam Piperacillin Sodium/Tazobactam | 54 | 54 | Under 11 | $12K |
| Ampicillin-Sulbactam Ampicillin Sod/Sulbactam Sod | 41 | 41 | Under 11 | $5,548 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 36 | 47 | 21 | $147 |
| Nitrofurantoin Nitrofurantoin Macrocrystal | 33 | 33 | Under 11 | $892 |
| Fosfomycin Tromethamine Generic | 32 | 32 | Under 11 | $1,612 |
| Doxycycline Hyclate Generic | 28 | 28 | 17 | $542 |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 26 | 29 | Under 11 | $1,145 |
| Levofloxacin Generic | 25 | 25 | 18 | $98.18 |
| Vancomycin Hcl Generic | 24 | 24 | Under 11 | $3,065 |
| Metronidazole Generic | 22 | 22 | 17 | $330 |
| Cefepime Hcl Generic | 17 | 17 | Under 11 | $2,341 |
Brand drugs: 95 claims; generic drugs: 827 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Celestine C Ishiekwene $23.34 ($23.34 in general payments such as food, travel and fees) from 1 company. The largest payer was Abbvie Inc. with $23.34.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 1 | $23.34 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.